Figure 3. At 2 weeks after crush SCI, there is substantial BrdU labelling of many cells, including a majority of GFAP positive scar-forming astrocytes and many Foxj1-tdT positive ependyma.

(a,b) Schematic of SCI lesion area shown and survey images of single channel and merged immunofluorescence comparing cells labeled for BrdU, Foxj1-tdT and GFAP in the lesion core (LC), ependyma (Ep) and astrocyte scar (AS). (c) Schematic of 5 dorso-ventral levels quantified and graph showing the percent of GFAP positive scar-forming astrocytes that are BrdU labeled and newly proliferated 2 weeks after SCI. n = 6 per group, *p < 0.001 (t-test). (d) Higher magnification of box in b showing the ependymal region and astrocyte scar adjacent to the lesion core. (e,f) Higher magnification orthogonal images of boxes in d showing many BrdU labeled cells positive for GFAP or Foxj1-tdT. (g–j) Detail orthogonal images of cells #1–4 labeled in (e,f) comparing the overlap of staining for GFAP and Foxj1-tdT within the ependymal layer and adjacent astrocyte scar.